This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of Afatinib or Nintedanib may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for Afatinib and Nintedanib in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
Fc-engineered CD33 mAb
The FDA granted BI 836858* Orphan Drug Designation for the treatment of acute myeloid leukaemia (AML) in June 2014 and for the treatment of myelodysplastic syndrome (MDS) in March 2017. Several Phase I and II studies investigating BI 836858 for the treatment of AML and MDS are ongoing.
About BI 836858
BI 836858’s mechanism of action
BI 836858 is a fully human immunoglobulin G (IgG) 1 CD33 mAb that binds to CD33 through antigen specific binding sites. BI 836858 has been engineered to bind with higher affinity to Fcƴ receptors (FcƴRIIIa) of effector cells, such as natural killer (NK) cells, than plasma IgG, thereby mediating more potent antibody-dependent cellular cytotoxicity (ADCC).1
Watch BI 836858’s mechanism of action
The role of CD33
CD33 is a cell surface antigen found on haematopoietic cells, primarily cells of myeloid lineage, for example monocytes and granulocytes; it is absent on haematopoietic stem cells.2,3 CD33 is widely expressed on malignant cells in AML2 and is a validated target, notably with the CD33-directed antibody-drug conjugate gemtuzumab ozagomicin showing improved overall survival.4 In addition, CD33 plays a direct role in the pathogenesis of MDS by acting as a receptor for S100A9 to initiate suppressive inflammatory signalling that can in turn lead to genomic instability.5
Preclinical studies with BI 836858 have shown high affinity binding of BI 836858 to CD33 and NK‑mediated ADCC against malignant CD33+ AML cells.1 Compared with the CD33 mAb, lintuzumab, BI 836858 showed slower internalisation resulting in higher levels of CD33 retained on the cell-surface and enhanced ADCC against human cells.1
BI 836858 is currently being investigated in Phase I/II trials for the treatment of the myeloid malignancies AML6-8 and MDS.9
AML, acute myeloid leukaemia; BSC, best supportive care; DLT, dose-limiting toxicity; GvHD, graft-vs-host disease; MDS, myelodysplastic syndrome; MTD, maximum tolerated dose; OS, overall survival; PFS, progression-free survival; RBC, red blood cell.
Vasu S, et al. Blood 2016;127(23):2879–89.
Ehninger A, et al. Blood Cancer J 2014;4:e218.
Nguyen DH, et al. Exp Hematol 2006;34(6):728–35.
Hills RK, et al. Lancet Oncol 2014;15(9);986–96.
Eksioglu EA, et al. Leukemia 2017; [Epub ahead of print].
ClinicalTrials.gov. NCT01690624. https://clinicaltrials.gov/ct2/show/NCT01690624 (Accessed: July 2017).
ClinicalTrials.gov. NCT02632721. https://clinicaltrials.gov/ct2/show/study/NCT02632721 (Accessed: July 2017).
ClinicalTrials.gov. NCT03207191. https://www.clinicaltrials.gov/ct2/show/NCT03207191 (Accessed: July 2017).
ClinicalTrials.gov. NCT03013998. https://clinicaltrials.gov/ct2/show/NCT03013998 (Accessed: July 2017).
ClinicalTrials.gov. NCT02240706. https://clinicaltrials.gov/ct2/show/study/NCT02240706 (Accessed: July 2017).
*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue